Navigation Links
CROS NT Ltd Announces Appointment of Andrew MacGarvey as CEO
Date:12/12/2013

LONDON, Dec. 12, 2013 /PRNewswire-iReach/ -- As part of the CROS NT Group global strategy, the company today announced the appointment of Andrew MacGarvey to the role of Chief Executive Officer and President from 1st January 2014. The move sees Paolo Morelli move into the role of Chairman for CROS NT allowing him to dedicate more time to PMH the holding company which oversees other life science businesses including ARITHMOS, its technology arm.

Paolo Morelli said, 'I am pleased to appoint Andrew as CEO of CROS NT, it is the culmination of a two-year plan. Andrew has overseen our expansion into the UK and USA and his combination of commercial and operational knowledge, alongside his passion for customer service, makes him the right candidate to take CROS NT forward. Andrew understands that we are a people business and I am confident he will continue to grow the company in a sustainable way. He has built a great team to support him and I look forward to watching them in the next phase of the CROS NT story.'

Morelli will devote more time to PMH, 'There are some great things happening within PMH and the time is right for me to dedicate more time to this project. I intend to work closely with ARITHMOS next year; the life sciences technology space has always excited me. Within ARITHMOS, we have the right portfolio of technologies and I want to make sure we are connecting with the market and getting these products to our customers'.

Andrew MacGarvey said 'It was a privilege to be asked to take on the role of CEO of CROS NT and I was delighted to accept the position. Paolo has built a company that reflects his philosophy. Every member of the team is highly valued, as are each and every one of our customers. My job is to continue to build the business, while ensuring we protect the unique way we work, and I am looking forward to the challenge. We are seeing growing demand for our offering, specialist statistical and data services delivered through a global organisation. Following our activities this year we are now able to deliver these services across the pharmaceutical, biotechnology and medical device sectors.'

MacGarvey brings over 15 years' experience in the sector to the role. He has worked at a number of CROs in senior positions covering both the commercial and operational areas. He has lived and worked in both the USA and the UK giving him an international perspective on the sector.

 

About CROS NT

In its 21st year, CROS NT is a global Contract Research Organization (CRO) specialized in clinical data services. With over 800 studies completed in a variety of therapeutic areas and indications, CROS NT has remained focused on biometrics including statistical consultancy, programming and analysis, clinical data management, medical writing, pharmacovigilance and life science technology solutions. We collect, integrate and analyze data from various sources and uses processes and technology to ensure excellent project governance, reporting and traceability. 

Media Contact: Mary Wieder, CROS NT Ltd, +44 (0)1908 488822, mary.wieder@crosnt.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE CROS NT
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. Biophysical Society announces speakers for Future of Biophysics Burroughs Wellcome Fund Symposium
2. SourceMedical Announces Hiring of Clinical Expert for ASC Division
3. KaloBios Announces Preliminary Phase 1 Results in Advanced Hematologic Malignancies with KB004, an Anti-EphA3 Monoclonal Antibody
4. Wyss Institute at Harvard University announces election of 2 faculty to Natl Academy of Inventors
5. Reproductive Health Matters announces publication of its latest themed issue: New development paradigm
6. Afterburn Fuel Review Announces the Launch of its New and Informative Website
7. VaxTrac Announces Continued Support for Expansion of Biometric-based Mobile Vaccine Registry Programs in Benin
8. AIBS announces winners of Faces of Biology photo competition
9. NERC announces the winner of its first photo and essay competition
10. Elsevier announces the launch of open access journal: Current Plant Biology
11. AVS Announces Its Major Award Winners of 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2016)... , June 2, 2016   The Weather Company ... announcing Watson Ads, an industry-first capability in which consumers will ... being able to ask questions via voice or text and ... Marketers have long sought an ... consumer, that can be personal, relevant and valuable; and can ...
(Date:6/1/2016)... NEW YORK , June 1, 2016 ... Biometric Technology in Election Administration and Criminal Identification to ... According to a recently released TechSci Research report, " ... Sector, By Region, Competition Forecast and Opportunities, 2011 - ... $ 24.8 billion by 2021, on account of growing ...
(Date:5/20/2016)... , May 20, 2016  VoiceIt is excited ... with VoicePass. By working together, VoiceIt ...  Because VoiceIt and VoicePass take slightly different approaches ... increases both security and usability. ... about this new partnership. "This marketing ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... CLEVELAND , June 27, 2016  Global ... average 4.6 percent through 2020 to $7.2 billion.  ... (food and beverages, cleaning products, biofuel production, animal ... and biotechnology, diagnostics, and biocatalysts). Food and beverages ... gains driven by increasing consumption of products containing ...
(Date:6/27/2016)... ... June 27, 2016 , ... Newly ... technologies, services and solutions to the healthcare market. The company's primary focus is ... manufacturing, sales and marketing strategies that are necessary to help companies efficiently bring ...
(Date:6/24/2016)... June 24, 2016 Epic Sciences unveiled ... cancers susceptible to PARP inhibitors by targeting homologous ... (CTCs). The new test has already been incorporated ... multiple cancer types. Over 230 clinical ... response pathways, including PARP, ATM, ATR, DNA-PK and ...
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
Breaking Biology Technology: